Clinical Trial Update: Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial of dipraglurant (ADX48621) in Parkinson disease patients on levodopa-based therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia Drug-induced
• Dyskinesias
• Parkinson Disease

Drugs mentioned

• Dipraglurant (dipraglurant)

Snippet

Sponsor: Addex Pharma S.A. | Conditions: Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2, Phase 3 | Status: TERMINATED